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Abstract
Stings by insects from the Hymenoptera order are known to cause life-threatening allergic reactions and impair life quality.
Despite the effectiveness of conventional vespid venom immunotherapy, more standardized and safer allergy vaccines are
required and recombinant hypoallergenic variants are important clinical tools. Antigen 5 is a major allergen of vespid
venoms and it was previously reported that Antigen 5 from Polybia scutellaris (Poly s 5) could be a hypoallergenic variant. In
this work we assess the immunological behavior and allergenic activity of Poly s 5 in order to explore its suitability for
specific immunotherapy. With this aim, recombinant Poly s 5 was expressed in Pichia pastoris and the presence of cross-
reactive epitopes with Pol a 5, a known allergenic Antigen 5, was investigated both at the IgG and IgE levels, by ELISA assays
and a basophil-mediator release assay respectively. A molecular model was also built to better understand the relationship
between immunological and structural aspects. In mice, Poly s 5 induced IgG antibodies which cross-reacted with Pol a 5.
However, Poly s 5 induced only minimal amounts of IgE and was a poor inducer of basophil-mediator release, even when
the cells were sensitized with Pol a 5-specific IgE. Moreover, Poly s 5-specific serum showed a specific protective activity and
was able to inhibit the Pol a 5-induced basophil degranulation. Structural analysis from the molecular model revealed that a
few amino acid substitutions in the N-terminal region of Poly s 5 should lead to an alteration of the surface topography and
electrostatic potential of the epitopes which could be responsible for its hypoallergenic behavior. These findings, taken as a
whole, show that Poly s 5 is likely a naturally occurring hypoallergenic Antigen 5 variant.
Citation: Vinzo´n SE, Marino-Buslje C, Rivera E, Biscoglio de Jime´nez Bonino M (2012) A Naturally Occurring Hypoallergenic Variant of Vespid Antigen 5 from
Polybia scutellaris Venom as a Candidate for Allergen-Specific Immunotherapy. PLoS ONE 7(7): e41351. doi:10.1371/journal.pone.0041351
Editor: Jacques Zimmer, Centre de Recherche Public de la Sante´ (CRP-Sante´), Luxembourg
Received April 17, 2012; Accepted June 20, 2012; Published July 23, 2012
Copyright:  2012 Vinzo´n et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partially supported by grants from the Universidad of Buenos Aires and the Consejo Nacional de Investigaciones Cientı´ficas y Te´cnicas de
la Repu´blica Argentina. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: s.vinzon@dkfz.de
¤ Current address: Research Program Infection and Cancer, Division of Viral Transformation Mechanisms, German Cancer Research Centre, Heidelberg, Germany.
Introduction
Allergies are the most common immune-mediated diseases, with
a current prevalence of up to 30% in industrialized countries [1].
Specific immunotherapy (SIT), which is based on the administra-
tion of increasing doses of allergen extracts to patients, is the only
specific and disease-modifying treatment for allergy, causing a
long-lasting symptom relief [2–4]. SIT involves several immuno-
logical mechanisms and it has been pointed out that a successful
treatment is associated with certain features. A number of studies
indicate that the induction of allergen-specific IgG antibodies plays
an important role in allergy vaccination, capturing the allergen
before reaching the effector cell-bound IgE and interfering with
the IgE-mediated antigen presentation [5].
Stings by insects of the Apidae family (honeybees and
bumblebees), those from the Vespidae family (Vespula, Dolicho-
vespula, Vespa and Polistes genera) and, in some regions, also of
the Formicidae family (ants), are one of the major causes of severe,
generalized, IgE-mediated hypersensitivity reactions that can be
fatal [6]. Immunotherapy for vespid allergy is at present carried
out with venom extracts (venom immunotherapy or VIT).
Although it has been demonstrated that VIT is clinically effective
[2], severe and life-threatening anaphylactic side effects may be
induced after the administration of crude allergen extracts.
Besides, extract–based immunotherapy includes the risk of
inducing new sensitizations. These drawbacks have limited the
widespread application of VIT. To avoid such effects, the
development of modified allergens with reduced allergenicity has
been proposed thus leading to their utilization in high doses with a
reduced risk of anaphylactic reactions. Moreover, the use of
recombinant proteins over natural allergen extracts, allows the
administration of a certain amount of the active antigen which can
be formulated in a standardized way [7].
Vespid venoms contain three major allergens: phospholipase
A1, hyaluronidase and Antigen 5 (Ag 5), the latter of still unknown
function [8]. New vaccination strategies are being focused on Ag 5
[9], which has been isolated from the venom of all the clinically
relevant species. The sting of Polybia scutellaris, a South American
wasp, does not cause allergic symptoms according to epidemio-
logical studies in the region where this vespid lives [10]. However,
it has been proven that its venom contains Ag 5 (Poly s 5) [11,12].
This protein shows 60.0–77.8% identity with Ag 5 s from other
vespids, the highest values corresponding to Polistes Ag 5 s thus
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reflecting their closely related evolutionary origin. Despite
sequence similarity, preliminary studies in mice suggested that
Poly s 5 constitutes a hypoallergenic variant. That is why we
pursued the recombinant expression of P. scutellaris Ag 5 in the
yeast Pichia pastoris, which was found to have the same
immunological behavior than the purified natural protein [13].
As most of the specific antibodies in venom immunized animals
are specific for discontinuous epitopes, such immunological
behavior should indicate a proper folding of the recombinant
protein.
In this work, we assess the immunological behavior and
allergenic activity of Poly s 5 in comparison to those of its more
allergenic homolog from Polistes annularis, Pol a 5. The presence of
Pol a 5-cross-reactive epitopes was investigated at the IgG as well
as the IgE level.
We discuss the finding that Poly s 5 has lower allergenic activity
in Balb/c mice and does not induce cross-linking of Pol a 5-
sensitized basophils, though it does generate cross-reactive IgG
antibodies (Abs) able to block Pol a 5-induced basophil degran-
ulation. Moreover, we analyze a molecular model of the antigen in
the context of these results, in order to extend the current
knowledge on the structural features which could contribute to Ag
5 allergenicity.
Results
Immunization of Mice with Poly s 5 Induces IgG Abs that
React with Pol a 5
Pol a 5, with a high degree of sequence similarity to Poly s 5,
was selected as its allergenic homolog. To search for the presence
of cross-reactive B-cell epitopes between Poly s 5 and Pol a 5,
specific mouse sera raised against either protein were tested for
their binding to solid-phase autologous or homologous protein by
direct ELISA (Figure 1). IgG Abs specific for either protein cross-
react with each other, as the homologous Ag 5 was recognized by
Abs raised against the other Ag 5. Specificity of the IgG cross-
reactivity was shown by the lack of reactivity of the control sera.
Moreover, both proteins induced comparable specific IgG titers
thus showing a similar immunogenicity. The efficiency of
autologous and homologous Ag 5 to stimulate a secondary
response in mice primed with either Ag 5 was also evaluated
(Table 1). Results showed that homologous Ag 5 (groups B and D)
was nearly as effective as autologous Ag 5 (groups A and C) in
stimulating secondary Ab responses. This provided additional
evidence that there is cross-reactivity between Poly s 5 and Pol a 5.
Allergenicity of Poly s 5
The allergenic potential of Poly s 5 was analyzed by means of a
degranulation assay using the rat basophilic leukemia cell line Rat
Basophilic Leukemia (RBL)-2H3 (Figure 2); individual mouse sera
were analyzed for their content of Ag 5-specific IgE. As judged by
the percentage of b-hexosaminidase release, Poly s 5 induced
significantly less specific IgE Abs than Pol a 5, thus showing a
reduced allergenicity.
In order to evaluate significant cross-reactivity at the IgE level,
rat basophils were loaded with IgE from mice immunized with Pol
a 5 and then exposed to either Pol a 5 or Poly s 5. Pol a 5 led to a
strong dose-dependent b-hexosaminidase release from basophils
(Figure 3), with a maximal value at concentrations of 1026 g/mL,
whereas Poly s 5 was not able to induce a significant mediator
release up to the concentration of 1024 g/mL thus indicating its
lesser allergenic activity as well as a low cross-reactivity at the IgE
level.
Protective Capacity of IgG Abs Induced by Poly s 5
We also investigated whether IgG Abs induced by immuniza-
tion with the hypoallergenic Poly s 5 could inhibit Pol a 5-specific
basophil degranulation in vitro by RBL cell mediator-release
inhibition experiments. Basically, Pol a 5 was preincubated with
increasing concentrations of mice anti-Poly s 5 Abs or a control
serum and then RBL cells preloaded with Pol a 5-specific IgE were
exposed to the immune complexes. Poly s 5-specific Abs
significantly inhibited the Pol a 5-induced mediator release from
RBL cells (Figure 4), while no inhibition was observed when the
allergen was preincubated with the same concentrations of
preimmune serum. These results confirm that cross-reactive IgG
Abs raised by Poly s 5 are also capable of blocking Pol a 5 binding
to effector cell-bound Pol a 5-specific IgE.
Analysis of the Molecular Model of Poly s 5
A molecular model of Poly s 5 was built by using the known
crystallographic structure of Ves v 5 as the template [14]. These
proteins share a 59% sequence identity; as expected, their
superposition showed a very similar overall structure (RMSD of
0.17 A˚ for 204 superimposed Ca; Figure S1) and displayed the a-
b-a sandwich core fold previously described for the superfamily,
maintaining all the secondary structural elements (strands A–D
and helices I–IV) [14]. The main structural differences are found
in sequence segments 8–10, 19–21, 23–28, 99–101 and 122–127
(Poly s 5 numbering). There is an additional short helix between
residues 24 and 27 in Poly s 5 due to a 25SSK27 insertion when
compared to Ves v 5 sequence; this helix was also found when
modeling Pol a 5 with the same template.
Mapping of Putative Cross-reactive Epitopes
Ag 5 s from the same genus are serologically cross-reactive and
a different degree of cross-reactivity has also been observed
between Ag 5 s from different vespid genera, reflecting their high
sequence similarity and the phylogenetic relationship between
organisms [15,16]. Structurally conserved allergen molecular
surfaces have been identified among different vespid Ag 5 s by
Henriksen et al. [14], providing the structural basis for the
observed allergic cross-reactivity. Five conserved surface patches,
proposed as putative cross-reactive epitopes, were revealed on the
Ves v 5 structure. These epitope candidates were mapped onto the
surface of the Poly s 5 model (Figure 5, Panels A and B).
Sequence alignment of vespid Ag 5 s with a proven cross-
reactivity (Figure 6) showed that of the 85 conserved residues, of
which four are changed only in Poly s 5: Asn5Lys, Val11Gly,
Gln110Lys and Val163Met (Poly s 5 numbering). Additionally, a Ser
insertion is present at position 25. Interestingly, 4 of these 5
changes are located in the conserved patches mentioned above
(Figure 5). The cyan patch (patch #1) has a conserved surface of
about 540 A˚2 and it harbors two of the changes: Asn5Lys and
Val11Gly, while the yellow patch (#3; 460 A˚2) has the Gln110Lys
substitution. The red one (#2; 660 A˚2) contains the 25Ser
insertion. Instead, the green and blue patches (#4 and #5; 1050
and 410 A˚2 respectively) are perfectly conserved on Poly s 5
surface. As appreciated in Figure 6, putative epitopes are formed
by non-contiguous residues. As regards red and cyan epitope
candidates, analysis of their structure shows that they distinctly
cover the N-terminal segment. When the surface electrostatic
potential of Poly s 5 is compared with that of Pol a 5 in the area
containing the putative epitopes (Figure 5, Panels C-H), some
drastic changes are revealed in the regions of Asn5Lys and
Gln110Lys substitutions; a blurring of the electropositive charge is
observed, as expected from the substitution of a positively charged
residue (Lys) for a neutral one (Asn or Gln). Moreover, a large
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disturbance of surface potential was observed in the region
surrounding 25Ser insertion; a more detailed inspection also
reveals a great change of the epitope topography. Furthermore,
when values of solvent accessible surface area per residue were
compared and analyzed in the alignment of Poly s 5 and Pol a 5
sequences, it became evident that 25Ser insertion in Poly s 5
modifies solvent exposure of several neighboring residues (Figure
S2), thus contributing to the loss of complementarity in this region.
Discussion
Vespid venom allergen Ag 5 has been characterized in great
detail from various species and several Ag 5 s have been cloned. In
this study we report an in-depth characterization of the first
naturally occurring Ag 5 hypoallergenic variant, Poly s 5. We also
explore the features that can make it suitable as a vaccine for safer
immunotherapy, replacing the widely used non-standardized
natural venom extracts. Two important requirements must be
fulfilled: (i) strong immunogenicity; (ii) the presence of B-cell
epitopes shared with the sensitizing allergen to induce blocking
Abs and hence be successful [17]. When investigating the immune
response elicited by Poly s 5 in mice we found that it induces a
Figure 1. Enzyme immunoassay of Poly s 5- or Pol a 5-specific mouse sera on solid-phase Poly s 5 and Pol a 5. Squares correspond to
Poly s 5-specific sera, which were assayed on Poly s 5 (&) or Pol a 5 (%) as the solid-phase antigen. Pol a 5-specific sera are designated by circles and
were assayed on Pol a 5 (N) or Poly s 5 (#) as solid-phase antigen. Closed triangles correspond to the preimmune sera. Mean values 6 S.E.M. are
shown.
doi:10.1371/journal.pone.0041351.g001
Table 1. Poly s 5 and Pol a 5 immunogenicity without
adjuvant.
Immunogena
Antibody titer for primary
immunogenb
Group Primary Boost Week 3 Week 5
Week 5/
Week 3
A Poly s 5 Poly s 5 ,,16102 4.36103 ..50
B Poly s 5 Pol a 5 ,,16102 4.46102 ..50
C Pol a 5 Pol a 5 1.16103 8.26103 7.4
D Pol a 5 Poly s 5 4.76102 1.66103 3.5
aGroups of four BALB/c mice were immunized with the primary immunogen at
week 0 and week 2 and with the secondary immunogen or boost at week 4.
bAntibody titer represents reciprocal serum dilution for one-third maximal
binding to solid phase Ag.
doi:10.1371/journal.pone.0041351.t001
Figure 2. Determination of Poly s 5 allergenic potential. RBL
cells were loaded with IgE from mice immunized with Poly s 5 (&) or
Pol a 5 (N) and then exposed to the corresponding autologous Ag 5.
Each symbol represents an individual serum. Percentages of b-
hexosaminidase release are displayed. Statistical analysis was performed
using a non-parametric Mann–Whitney U-test to compare release
between the groups.
doi:10.1371/journal.pone.0041351.g002
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robust Poly s 5-specific IgG response, including IgG Abs that
cross-react with Pol a 5, a clinically relevant allergen. Moreover,
those Abs showed a specific protective activity and inhibited the
Pol a 5-induced basophil degranulation when tested in RBL
assays. It is important to point out that hypoallergens which induce
a robust IgG response in BALB/c mice will also likely induce
blocking IgG Abs in humans [18].
The risk of using allergenic extracts in immunotherapy makes
the development of new strategies such as the use of hypoaller-
genic variants relevant. We found that Poly s 5, even when
administered with a strong adjuvant, induces a lower IgE level
upon immunization of mice thus exhibiting reduced allergenicity
in vivo. On the other hand, Poly s 5 induces a weaker mediator
release than Pol a 5 in assays with Pol a 5-sensitized RBL cells
(Figure 3), thus indicating that it also displays low cross-reactivity
with this allergen at the IgE level.
We undertook a comparative study of structural aspects of
Poly s 5 against those of Ves v 5 to contribute to the
Figure 3. IgE cross-reactivity between Poly s 5 and Pol a 5. RBL cells were loaded with IgE from mice immunized with Pol a 5 and then
exposed to increasing concentrations of either Pol a 5 (N) or Poly s 5 (#). Mean percentages of b-hexosaminidase release of duplicates 6 S.E.M. are
displayed.
doi:10.1371/journal.pone.0041351.g003
Figure 4. Inhibition of Pol a 5-induced RBL degranulation by Poly s 5-specific Abs. RBL cells were loaded with Pol a 5-specific mouse IgE
and then exposed to Pol a 5, which was preincubated with increasing concentrations of mouse Poly s 5-specific serum (&) or preimmune serum (m).
Mean percentages of b-hexosaminidase release of duplicates6 S.E.M. are displayed. Statistical significance was assessed using an unpaired Student’s
t test (**p,0.01; ***p,0.001 vs. preimmune serum).
doi:10.1371/journal.pone.0041351.g004
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understanding of the structural requirements for Ag 5 allerge-
nicity. Ag 5 s sequence alignment has shown a high degree of
similarity supporting a common protein fold [19]. Additionally,
such similarity allows the existence of conserved surface areas
that constitute candidates for epitopes defined by cross-reactive
antibodies [20]. Cross-reactivity between members of the Ag 5
family is well established, and five highly conserved regions on
the surface of Ves v 5 were proposed as putative epitopes.
Antigen-antibody interaction studies indicate that the surface
area buried in an epitope is about 600–900 A˚2 [21]; reduction of
this area might cause a decrease in the Ab affinity constant. Major
factors determining binding affinity are a perfect fit in the
topography of the complementary surfaces of the epitope/
Figure 5. Analysis of the surface of Poly s 5 molecular model. (A and B) Views of Poly s 5 model. In Panel B the molecule is rotated 180u on
the y axis with respect to Panel A. Conserved surface patches proposed are numbered and colored. Amino acid changes exclusive for Poly s 5 and
located on the molecular surface are in purple and substitutions are indicated by the single-letter amino acid code. The surface electrostatic potential
for Poly s 5 (C, D and E) and Pol a 5 (F, G and H) is represented by a blue to red scale corresponding to25 kT to +5 kT respectively. In panels A, C and
F the molecules have the same orientation; the same is true for panels B, D and G. In panels E and H the molecules are oriented to show the red
patch.
doi:10.1371/journal.pone.0041351.g005
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paratope interaction [21], as well as the electrostatic complemen-
tarity of the interacting surfaces [22]. Our analysis of the
molecular model of Poly s 5 shows that only the green and blue
patches, as defined by Henriksen et al. [14], are conserved in Poly
s 5. However, based on sequence conservation and structural
characteristics, the blue patch has been proposed to be a cavity
implied in the yet unknown Ag 5 activity, thus not the best
candidate for a cross-reactive epitope [14]. Therefore, it is likely
that the green patch would be at least partially responsible for the
cross-reactivity between Poly s 5 and Pol a 5. On the other hand,
the non-conserved residues in the cyan, red and yellow putative
epitopes clearly contribute to differences in the local molecular
surface and the electrostatic potential which could affect the
interaction with antibodies. Analysis of known IgE epitopes
indicates that the propensity of Lys being in an epitope is
significantly higher than in any other protein-protein interface
[23]; moreover, the substitution of even a single Lys can cause an
electrostatic disturbance and abolish IgE binding [24,25]. It is
possible that the presence of Lys 5 and 106 (Ves v 5 numbering) is
important for IgE binding and their absence plays a role in the
lack of allergenicity of Poly s 5.
King et al. [26] have reported that the dominant B cell epitopes
of Ves v 5 are in the N-terminal region. Three of the 4 surface-
exposed residue changes in Poly s 5 are located in the protein N-
terminal area (Asn 5, Val 11, and Ser 25), substantially changing
the red and cyan patches properties. The cyan patch has two
substitutions, including the mentioned Asn5Lys, whereas the
insertion of 25Ser in the red patch drastically modifies its shape
and electrostatic potential. It is interesting to highlight that allergic
cross-reactivity requires the cross-linking of receptor bound IgE
Abs on the surface of a mast cell or basophil through simultaneous
interaction with two conserved surface areas of the protein [20].
This implies that, in order to detect cross-reactivity by the RBL-
cell assay, at least two shared cross-reactive epitopes are needed.
Our molecular model of Poly s 5 supports the lack of IgE cross-
reactivity given that only one putative epitope is conserved. Future
studies will include the construction of mutants involving the
aforementioned positions to test this hypothesis.
Reduction of IgE binding by substituting highly solvent exposed
key amino acids located on conserved surface areas, together with
the use of a universal cross-reactive reagent, have been proposed
for immunotherapy related to vespid allergens [14,27]. The Ag 5
Figure 6. Sequence alignment of vespid Ag 5 s. From top to bottom: Ves f 5, Vespula flavopilosa Ag 5 (P35783); Ves v 5, V. vulgaris Ag 5
(Q05110); Ves m 5, V. maculifrons Ag 5 (P35760); Ves g 5, V. germanica Ag 5 (P35784); Ves p 5, V. pensylvanica Ag 5 (P35785); Ves vi 5, V. vidua Ag 5
(P35787); Ves s 5, V. squamosa Ag 5 (P35786); Vesp c 5.02, Vespa crabro Ag 5 (P35782); Vesp c 5.01, V. crabro Ag 5 (P35781); Vesp m 5, V. mandarinia
Ag 5 (P81657); Dol m 5.01, Dolichovespula maculata Ag 5 (P10736); Dol a 5, D. arenaria Ag 5 (Q05108); Dol m 5.02, D. maculata Ag 5 (P10737); Pol e 5,
Polistes exclamans Ag 5 (P35759); Pol a 5, P. annularis Ag 5 (Q05109); Pol f 5, P. fuscatus Ag 5 (P35780); Pol d 5, P. dominulus Ag 5 (P81656); Pol g 5, P.
gallicus Ag 5 (P83377); Poly s 5, Polybia scutellaris Ag 5 (Q7Z156). Fully conserved residues of the five (#1–5) proposed epitopes are on cyan, red,
yellow, green and blue background respectively. Residues which are non-conserved or conservatively substituted are on white and gray background
respectively. Residues exclusively changed in Poly s 5 are on purple background and marked with arrows. Numbering corresponds to the Poly s 5
sequence.
doi:10.1371/journal.pone.0041351.g006
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from P. scutellaris, whose structural and immunological features are
described herein, is a naturally occurring variant with minimal
allergenic activity but a strong immunogenicity and IgG cross-
reactivity with allergenic homologs. Taken as a whole, epidemi-
ological studies and results obtained herein lead us to suggest that
Poly s 5 could be a promising candidate for a new strategy of
specific immunotherapy for vespid venom allergy.
Materials and Methods
Ethics Statement
All animal experimental procedures were performed in accor-
dance to the Argentinean National Research Council Directive
RD_Nu 1047/05 for ethical biomedical research in laboratory
animals. The ethics committee on the use and care for laboratory
animals at the Animal House of the School of Exact and Natural
Sciences (University of Buenos Aires) approved all the procedures
used in this study.
Allergens
Recombinant Poly s 5 and Pol a 5 were produced in P. pastoris
and purified as previously described [13]. A plasmid to express the
recombinant Pol a 5 in P. pastoris was kindly provided by Dr. T. P.
King [26].
Immunization Protocols
Groups of 6 male BALB/c mice were immunized i.p. 5 times at
2-week intervals with 0.2 mL of 10 mg/mL immunogen (Poly s 5
or Pol a 5) with 5 mg/mL alum (ImjectAlumH, Pierce Chemical
Company, Rockford, IL, USA) in PBS. One group was
immunized only with PBS as a control. Mice were bled 1 week
after the last injection and sera were collected.
For measurement of in vivo immunogenicity, groups of 4 male
BALB/c mice were immunized i.p. twice at a 2-week interval with
0.2 mL of 10 mg/mL of the primary immunogen (Poly s 5 or Pol a
5) without adjuvant. After 2 weeks, mice were injected with
0.2 mL of 10 mg/mL of either the primary immunogen or the
homologous Ag 5 as a boost. Sera were collected 1 week after the
second and third injections.
Measurement of Specific and Cross-reactive IgG
Antibodies by ELISA
Microtiter plates (Immuno96 MicroWellTM Plates Nunc Max-
iSorpTM) were coated overnight at 4uC with Poly s 5 or Pol a 5
(2 mg/mL in 0.05 M Tris-HCl buffer, pH 8.0) and thereafter
blocked for 1 h with TBS containing 0.05% Tween-20 and 0.5%
BSA. Duplicate wells were then incubated overnight at 4uC with
mouse serum diluted in the incubation buffer (TBS containing
0.05% Tween 20 and 0.25% BSA). After washing, bound specific
mouse IgG was detected with biotinylated goat anti-mouse IgG
and an avidin-alkaline phosphatase conjugate (Invitrogen, San
Diego, CA, USA). Color development was performed by addition
of p-nitrophenyl phosphate (Sigma, St Louis, MO, USA) for
30 min, and absorbance at 405 nm was measured. Curves were
fitted by nonlinear regression with GraphPad Prism 5.0 (Graph-
Pad Software, San Diego, CA, USA).
Rat Basophilic Leukemia (RBL) Cell Mediator-release
Experiments
The allergenic potential of each Ag 5 was studied by the RBL
assay [28]. Briefly, RBL-2H3 cells (ATCC CRL-2256TM, Rock-
ville, MD, USA) were plated in 96-well flat-bottomed tissue culture
plates (46104/well; BD FalconTM, BD Biosciences, San Jose, CA,
USA) and passively sensitized for 2 h with mice sera diluted 1:50.
After washing the cells in Tyrode’s buffer (137 mM NaCl,
2.7 mM KCl, 0.5 mM MgCl2, 1.8 mM CaCl2,
0.4 mM NaH2PO4, 5.6 mM D-glucose, 12 mM NaHCO3,
10 mM HEPES and 0.1% BSA, pH 7.2), cross-linking of the
FceR-bound IgE was induced by adding 100 ng/mL Ag 5 in
Tyrode’s buffer for 1 h at 37uC. Spontaneous release was
measured by incubation of sensitized RBL-2H3 cells with Tyrode’s
buffer and total release was obtained after addition of 1% Triton
X-100 (Sigma Chemical Co., St. Louis, MO, USA) to the
medium. b -hexosaminidase release into the supernatant was
measured by enzymatic cleavage of p-nitro-N-acetyl-b-D-glucosa-
minide (1.3 mg/mL in 50 mM citrate buffer, pH 4.5; Sigma).
After 1-h substrate incubation, the reaction was stopped by
addition of 0.4 M glycine buffer, pH 10.5, and the absorbance at
405 nm was determined. Results are expressed as percentage of
the total release minus that of the spontaneous release.
The same protocol was utilized for determination of cross-
reactivity at the IgE level, although serial dilutions (10210–1024 g/
mL) of the cross-linking autologous or homologous Ag 5 were
used.
The ability of Poly s 5-specific serum to inhibit Pol a 5-induced
degranulation of RBL cells was determined as follows. Pol a 5
(0.01 mg/mL) was preincubated with different dilutions (0, 2.5, 5,
and 10%) of mouse anti-Poly s 5, or, as a control, of a preimmune
mouse serum, in Tyrode’s buffer for 2 h at 37uC. The mixtures
were then exposed to RBL cells passively sensitized with Pol a 5-
specific mouse IgE. Mediator-release analysis was performed as
described above.
Sequence Alignment and Molecular Modeling
Ag 5 sequences were retrieved from UniProtKB. Multiple
sequence alignment was performed with CLUSTAL X [29] and
adjusted manually. Models were built by using the crystal structure
of Vespula vulgaris Ag 5 (Ves v 5, PDB 1QNX) as the template and
the program suite Modeller 9v2 [30]. The stereochemical quality
of the models was checked using PROCHECK [31] and Verify3D
[32]. All graphical molecular representations were generated using
PyMol (DeLano Scientific LLC, San Carlos, CA, USA, http://
www.pymol.org). The template and models alpha carbon
backbones were superimposed and the RMSD was calculated
with the program SWISS-PDB Viewer [33]. Electrostatic
potentials were calculated with Delphi [34]. The inner and outer
dielectric constants applied to the protein and the solvent, were
fixed at 4.0 and 80.0 respectively, and calculations were performed
keeping a 0.15 M ionic strength. Values of solvent accessible
surface area were obtained with the program MOLMOL [35]; a
radius of 1.4 A˚ for the water molecule was assumed.
Supporting Information
Figure S1 Superimposition of Ves v 5 (orange) and
modeled Poly s 5 (purple) structures. Molecules are shown
in the ribbon representation. Dashed lines comprise the five
regions (a–e) with the worst adjustment: residues 8–10 (a), 19–21
(b), 23–28 (c), 99–101(d) and 122–127(e) corresponding to Poly s 5
numbering.
(TIFF)
Figure S2 Solvent accessible surface area per residue. It
was calculated for Poly s 5 (dark gray line) and Pol a 5 (orange line)
models. Values represent the percentage of solvent exposed area
for each individual residue, compared to that of a Gly-X-Gly
tripeptide. Dashed line represents the limit above which a residue
is considered as exposed (30% exposure). Values are aligned with
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the corresponding alignment of both proteins. Colored areas
represent the conserved surface patches shown in Figures 5 and 6.
(TIFF)
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